Biotech · Private company
Neurocentria, Inc.
Track this companyFree. Adds Neurocentria, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials60 recruiting or active
Pipeline programs6From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline6
- NRCT-101-SRPhase 3 · ADHDClinicalTrials.gov · fetched Nov 12, 2026
- NRCT-101SRPhase 3 · Attention-Deficit/Hyperactivity Disorder (ADHD)ClinicalTrials.gov · fetched Nov 12, 2026
- High Dose MMFS-205-SRPhase 2 · AnxietyClinicalTrials.gov · fetched Nov 12, 2026
- Low Dose MMFS-205-SRPhase 2 · AnxietyClinicalTrials.gov · fetched Nov 12, 2026
- MMFS-205-SRPhase 2 · Alzheimer DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- NRCT-101SR, NRCT-202XRPhase 2 · ADHDClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials6
- A Phase 2 Randomized Double-Blind, Parallel, Adaptive-Design, Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR With NRCT-202XR Compared to NRCT-202XR Alone in Subjects With Attention-Deficit/Hyperactivity DisorderPHASE2 · TERMINATED · started Feb 25, 2025ClinicalTrials.gov NCT06673368 · fetched Nov 12, 2026
- Study to Evaluate NRCT-101SR in Pediatric Subjects With ADHDPHASE2_PHASE3 · TERMINATED · started Jan 25, 2024ClinicalTrials.gov NCT06215144 · fetched Nov 12, 2026
- Study to Evaluate NRCT-101SR in Adult Attention Deficit Hyperactivity Disorder (ADHD)PHASE2_PHASE3 · COMPLETED · started Feb 25, 2023ClinicalTrials.gov NCT05683249 · fetched Nov 12, 2026
- Comparison of MMFS Dosages in Older AdultsPHASE2 · COMPLETED · started Jul 23, 2018ClinicalTrials.gov NCT03601169 · fetched Nov 12, 2026
- Efficacy and Safety of MMFS in Early ADPHASE2 · COMPLETED · started Mar 20, 2018ClinicalTrials.gov NCT03531684 · fetched Nov 12, 2026
- Effect of MMFS-202-302 on Cognitive Enhancement in SchizophreniaPHASE2 · COMPLETED · started Aug 1, 2014ClinicalTrials.gov NCT02237235 · fetched Nov 12, 2026